90-Second Read: Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism

Traws Pharma announces a novel antiviral agent targeting Hantavirus, Ebola, and Lassa, advancing cli Enter your email to receive free breaking news alerts and insights related to TRAW. This innovative combination therapy employs a dual-strike mechanism to deplete host cell nucleotides, effectively starving viruses and enhancing therapeutic potency while minimizing toxicity. Traws Pharma's new broad-spectrum antiviral agent targets Hantavirus, Ebola, and Lassa using a novel dual-strike mechanism. Traws Pharma is currently collaborating with health authorities such as the CDC, NAFDAC, and the African Medicines Agency to expedite clinical development and ensure global access to the new therapy.

Traws Pharma plans to collaborate with health agencies like the CDC and NAFDAC to fast-track clinical development. The Company is advancing non-clinical development and evaluating the therapeutic combination in validated animal models of Hantavirus and Ebola. Recognizing the critical importance of regional healthcare organizations and rapid deployment, Traws Pharma will build on existing contacts in Nigeria, in particular its relationship with the NAFDAC to develop sustainable, local manufacturing of drug products. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire.

With a focus on sustainable local manufacturing in Nigeria, Traws aims for equitable access to its life-saving therapeutics in Africa, poised to transition from laboratory success to frontline applications in public health. The investigational combination utilizes a unique "dual-strike" mechanism of action that hijacks host cell pathways to force viral eradication. David Pauza, PhD, Chief Science Officer of Traws Pharma. Redfield, MD Chief Medical Officer of Traws Pharma and former Head of the CDC.

We have seen 13 institutional investors add shares of $TRAW stock to their portfolio, and 15 decrease their positions in their most recent quarter. Importantly, both components of the combination have been safely evaluated in human studies as single agents. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements.